United Therapeutics (UTHR) News Today $358.93 -7.46 (-2.04%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Hennion & Walsh Asset Management Inc. Reduces Position in United Therapeutics Co. (NASDAQ:UTHR)Hennion & Walsh Asset Management Inc. lessened its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 45.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,327 shares of the biotechnology companJanuary 20 at 3:31 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Holdings Cut by Wedge Capital Management L L P NCWedge Capital Management L L P NC trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 11.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 79,447 shares of the biotechnologJanuary 18 at 6:11 AM | marketbeat.comAssenagon Asset Management S.A. Has $19.45 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)Assenagon Asset Management S.A. reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 12.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,115 shares of the biotechnology compaJanuary 18 at 3:40 AM | marketbeat.comUSA Financial Formulas Has $307,000 Stake in United Therapeutics Co. (NASDAQ:UTHR)USA Financial Formulas boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 856.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 870 shares of the biotechnology compJanuary 17 at 4:58 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Short Interest UpdateUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) was the recipient of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 1,920,000 shares, a decline of 14.3% from the December 15th total of 2,240,000 shares. Approximately 4.4% of the company's shares are short sold. Based on an average daily trading volume, of 317,200 shares, the days-to-cover ratio is presently 6.1 days.January 16, 2025 | marketbeat.com1,276 Shares in United Therapeutics Co. (NASDAQ:UTHR) Acquired by Wedmont Private CapitalWedmont Private Capital acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,276 shares of the biotechnolJanuary 16, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Upgraded to Strong-Buy at StockNews.comStockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday.January 16, 2025 | marketbeat.comUnited Therapeutics: Strong Market Position and Growth Prospects with Strategic Pipeline and Capital ManagementJanuary 15, 2025 | markets.businessinsider.comBurney Co. Raises Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)Burney Co. boosted its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 113.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,922 shares of the biotechnology company'sJanuary 15, 2025 | marketbeat.comMichael Benkowitz Sells 10,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockJanuary 15, 2025 | insidertrades.comUnited Therapeutics (NASDAQ:UTHR) to Provide Business Update at J.P. Morgan Healthcare ConferenceJanuary 15, 2025 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) COO Sells $3,646,200.00 in StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $364.62, for a total value of $3,646,200.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at $939,625.74. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.January 14, 2025 | marketbeat.comNordea Investment Management AB Sells 75,464 Shares of United Therapeutics Co. (NASDAQ:UTHR)Nordea Investment Management AB trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 95.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,378 shares of the biotechnology company'January 13, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Price Target Raised to $475.00January 11, 2025 | americanbankingnews.comUnited Therapeutics price target raised to $475 from $415 at UBSJanuary 9, 2025 | markets.businessinsider.comUnited Therapeutics (NASDAQ:UTHR) Stock Rating Lowered by StockNews.comStockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Wednesday.January 8, 2025 | marketbeat.comUBS Group Increases United Therapeutics (NASDAQ:UTHR) Price Target to $475.00UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday.January 8, 2025 | marketbeat.comUnited Therapeutics snaps up another property near Silver Spring HQJanuary 8, 2025 | bizjournals.comCWA Asset Management Group LLC Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)CWA Asset Management Group LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 5,425 shares of the biotechnology company's stJanuary 7, 2025 | marketbeat.comUnited Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | gurufocus.comUnited Therapeutics Corp (UTHR) to Present at J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | gurufocus.comJPMorgan Chase & Co. Has $69 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)JPMorgan Chase & Co. raised its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 35.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 192,546 shares of the biotechnology company's stock after buyinJanuary 4, 2025 | marketbeat.comInsider Sell: Nilda Mesa Sells Shares of United Therapeutics CorpDecember 31, 2024 | gurufocus.comNilda Mesa Sells 255 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Nilda Mesa sold 255 shares of the stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the sale, the director now owns 5,528 shares of the company's stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.December 31, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) COO Sells $3,566,800.00 in StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $356.68, for a total transaction of $3,566,800.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $919,164.36. This trade represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.December 31, 2024 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Upgraded to "Strong-Buy" at StockNews.comStockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Monday.December 30, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the fifteen brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, tDecember 30, 2024 | marketbeat.comWe Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With EaseDecember 29, 2024 | finance.yahoo.comUnited Therapeutics Corporation (UTHR): Among the Cheap Healthcare Stocks to Buy Heading Into 2025December 28, 2024 | insidermonkey.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) COO Sells 10,000 Shares of StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $361.95, for a total value of $3,619,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $932,745.15. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.December 26, 2024 | marketbeat.comIs United Therapeutics (UTHR) the Best Performing Biotech Stock in 2024?December 24, 2024 | insidermonkey.comPrincipal Financial Group Inc. Has $40.31 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)Principal Financial Group Inc. decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 28.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 112,473 shares of the biotechnology company's stock afterDecember 24, 2024 | marketbeat.comHere are Updates on United Therapeutics Corp. (UTHR)December 23, 2024 | insidermonkey.comInsider Sell: Louis Sullivan Sells 26,209 Shares of United Therapeutics CorpDecember 19, 2024 | gurufocus.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Sells $9,781,722.98 in StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Louis W. Sullivan sold 26,209 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares of the company's stock, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.December 19, 2024 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Trading Down 4.4% - Here's WhyUnited Therapeutics (NASDAQ:UTHR) Stock Price Down 4.4% - Here's What HappenedDecember 18, 2024 | marketbeat.comCautious Hold: United Therapeutics’ Promising UKidney Progress Amidst Regulatory HurdlesDecember 18, 2024 | markets.businessinsider.comUnited Therapeutics President Michael Benkowitz sells $3.7M in sharesDecember 17, 2024 | markets.businessinsider.comUnited Therapeutics Announces Successful World’s First UKidney TransplantDecember 17, 2024 | finance.yahoo.comWho wants a pig organ? Patients sick and tired of waiting years for a transplantPeople worried they'll never get a scarce human transplant want to know when they might get a pig kidney insteadDecember 17, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Franklin Resources Inc.Franklin Resources Inc. boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 97.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 250,719 shares of the biotechnology company's stockDecember 16, 2024 | marketbeat.comLord Abbett & CO. LLC Buys 46,170 Shares of United Therapeutics Co. (NASDAQ:UTHR)Lord Abbett & CO. LLC raised its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 29.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 201,695 shares of the biotechnology coDecember 15, 2024 | marketbeat.comTidal Investments LLC Purchases 2,803 Shares of United Therapeutics Co. (NASDAQ:UTHR)Tidal Investments LLC lifted its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 33.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,272 shares of the biotechnology company's stock after acquiring an additional 2,80December 15, 2024 | marketbeat.comBarclays PLC Sells 15,445 Shares of United Therapeutics Co. (NASDAQ:UTHR)Barclays PLC trimmed its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 20.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 58,594 shares of the biotechnology company's stock after selling 15,445 shares during the period. BarclDecember 15, 2024 | marketbeat.comOddo BHF Asset Management Sas Invests $1.70 Million in United Therapeutics Co. (NASDAQ:UTHR)Oddo BHF Asset Management Sas bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,738 shares of the biotechnology company's stoDecember 14, 2024 | marketbeat.comGeode Capital Management LLC Purchases 45,566 Shares of United Therapeutics Co. (NASDAQ:UTHR)Geode Capital Management LLC increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 4.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,094,015 shares of the biotechnology company's stDecember 14, 2024 | marketbeat.comRetirement Systems of Alabama Sells 12,481 Shares of United Therapeutics Co. (NASDAQ:UTHR)Retirement Systems of Alabama trimmed its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 8.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 129,372 shares of the biotechnology company's stocDecember 13, 2024 | marketbeat.com21,448 Shares in United Therapeutics Co. (NASDAQ:UTHR) Acquired by Tri Ri Asset Management CorpTri Ri Asset Management Corp purchased a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 21,448 shares of the biotechnology company's stock, valued at approximately $7,686,000December 13, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Stock Holdings Lessened by Nomura Asset Management Co. Ltd.Nomura Asset Management Co. Ltd. cut its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 10.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,637 shares of the bDecember 12, 2024 | marketbeat.comEP Wealth Advisors LLC Invests $576,000 in United Therapeutics Co. (NASDAQ:UTHR)EP Wealth Advisors LLC bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The fund bought 1,608 shares of the biotechnology company's stock, valued at approximately $576,000. A number of otherDecember 12, 2024 | marketbeat.com Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Media Mentions By Week UTHR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UTHR News Sentiment▼1.290.44▲Average Medical News Sentiment UTHR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UTHR Articles This Week▼1310▲UTHR Articles Average Week Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALNY News BIIB News NBIX News INCY News BMRN News EXEL News EXAS News RGEN News HALO News MDGL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UTHR) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
